D-689-2013 Class III Terminated
FDA drug recall D-689-2013 was initiated by Teva Pharmaceuticals USA, Inc. on Mar 15, 2013 and is designated Class III. Reason for recall: Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing The recall status is terminated (terminated Jan 15, 2014). Affected quantity: 154,536 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 17, 2013
- Initiation Date
- Mar 15, 2013
- Termination Date
- Jan 15, 2014
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 154,536 cartons
Product description
Errin (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tablets each, 28 day regimen, Rx Only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0555-0344-58
Reason for recall
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Distribution pattern
Nationwide and Puerto Rico
Code information
Lot #s: 33801773A, Exp 7/14; 33801774A, Exp 8/14; 33801775A, 33801776A, Exp 9/14; 33802427A, 33802428A, 33802429A, 33802430A, Exp 12/14; 33802925A, 33802926A, Exp 3/15; 33803383A, 33803384A, 33803385A, 33803387A, 33803685A, Exp 6/15.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-689-2013
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026